All News

RheumNow Podcast square

Eating Crow (10.10.2025)

d Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

Read Article
MRI.scan

Whole Body MRI for Arthritis

d Jack Cush, MD

Whole-body MRI (wbMRI) reviews have increasingly appeared in the medical literature, owing to better scanners, faster imaging times and reduced costs. Used of such non-oncologic musculoskeletal imaging provides high-contrast resolution images of the entire body or selected regions screening, diagnosis, staging, and surveillance purposes.

Read Article
MGUS,SPEP,Gamma

Review: Monoclonal Gammopathy of Undetermined Significance

d Jack Cush, MD

NEJM has reviewed the common hematologic/immunologic finding of "monoclonal gammopathy of undetermined significance" (MGUS) - a common premalignant plasma-cell proliferative disorder found in approximately 5% of those over age of 50 years.

Read Article
Fracture%20bone.png (keep)

NY Times on Osteoporosis in Men

d Jack Cush, MD

The NY Times has addressed the problem of osteoporosis in men noting a need for increased awareness and screening. Takeaways:

Read Article
PSA2L.jpg

Gender Complexities in Psoriatic Arthritis Treatment Outcomes

d Jack Cush, MD

Analysis of a German psoriatic arthritis (PsA) patients registry demonstrates sex-specific differences regarding clinical manifestation and treatment outcomes, especially with regard to drug discontinuations.

Read Article
pill,pain,med,hand

Tramadol not effective at chronic pain

d EurekAlert!

The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine.

Read Article
op.compare.jpg

Osteoporosis Screening in High-Risk Men

d Jack Cush, MD

A Veterans Affairs (VA) Health Systems study of older male veterans found benefits of a remote model of screening that significantly improved osteoporosis screening, treatment, and adherence compared with usual care, with high patient and clinician acceptance.

Read Article
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect: • KOL videos • Clinical trial highlights • Daily faculty recaps • Live streaming #ACR25 #Rheumatology #ClinicalTrials https://t.co/M5sxhWz2EK
Dr. John Cush RheumNow ( View Tweet)
HMGCR Abs is assoc w/ necrotizing myopathy. Review of 78 pts w/ HMGCR IMNM. 31 had overlap w/ higher MMT-score, less muscle weakness, more ILD, arthralgia, wt loss & rash. 12 had musc. dystrophy like dz w/ earlier onset, longer duration, less myalgia & extramuscular Sxs https://t.co/RpzZI0zI7E
Dr. John Cush RheumNow ( View Tweet)
Prediction of D2T-RA. Model was trained on BRASS pts (700; 16% w/ D2T-RA) & validated on CERTAIN pts (2,070; 28% D2TRA). PRO's were strongest predictors. Moderate predictive accuracy (C-index of 0.64 & 0.62) w/ functional status, pain, fatigue, and global Dz activity https://t.co/uv3uGYIRFb
Dr. John Cush RheumNow ( View Tweet)
Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH

Links:

Dr. John Cush RheumNow ( View Tweet)
Osteoporosis Screening in High-Risk Men A VA Health Systems study of older male veterans found benefits of a remote model of screening that significantly improved osteoporosis screening, treatment, and adherence compared with usual care, with high patient and clinician https://t.co/Kt3mJLahdq
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 42 adult Still' pts Rx after 2010 w/ IL‐1 inhib if given < 6 mos (early) or > 6mos of Sxs. Early IL-1i had more inactive dz (CID)(67% vs 38%; P = 0.17) & steroid d/c w/in 6 mos. 10 major flares observed (62% after IL‐1i suspension or spacing) https://t.co/uD1meQuYvj
Dr. John Cush RheumNow ( View Tweet)
Not all difficult-to-treat RA will have rapid radiographic progression A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy. https://t.co/WrwyeW5qsj
Dr. John Cush RheumNow ( View Tweet)
Systematic review of Still's Dz (240 articles, 95 sJIA, 134 AOSD, 23,136 pts); sJIA Dx by ILAR in 78% & AOSD used Yamaguchi criteria 98%. While clinical and lab findings were matched betw AOSD & sJIA, there was variability in MAS , outocmes & trajectory. Standarization needed

Dr. John Cush RheumNow ( View Tweet)

Optimizing DMARD Therapy in Rheumatoid Arthritis A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare. https://t.co/37O3mAulGy https://t.co/y7OkkzRZUg

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow is LIVE from #ACR25 Oct 24–29. KOL perspective videos, clinical-trial highlights, daily recaps & live streaming—all in one feed. https://t.co/pPwJNOyEFU
Dr. John Cush RheumNow ( View Tweet)
Associations in Rheumatology (10.3.2025) Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow. https://t.co/pnLoquR4By https://t.co/PKJuxMGrZy

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study of 62 lupus nephritis pts rx w/ induction therapy - MMF vs IV CYC x 6 mos followed by MMF for next 6 mos. At 1 year complete renal remission (CRR) seen in 77% MMF vs 29% CYC. https://t.co/wG2Qrn1PSU https://t.co/gP8XYO4q92

Links:

Dr. John Cush RheumNow ( View Tweet)
Ethnic Minority Rheumatoid Arthritis Consortium registry study of 1315 RA pts (Dz duration 10yrs) incl 29% Blacks found Blacks in less remission(~2-fold by DAS28), more mod-hi dz activity, & frequently met active disease eligibility for RCTs. https://t.co/SfkVUB1GBz https://t.co/OwvmALHPFA

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×